Finally, we demonstrate that the clinically available inhibitor Ruxolitinib synergises with cisplatin in the induction of apoptosis in cervical cancer cells, suggesting that pharmalogical targeting of JAK2 may have therapeutic benefit in HPV-driven malignancies. Here, JAK2 is linked to cervical carcinoma.